{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:52:48Z","timestamp":1790175168053,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2001,11]]},"DOI":"10.1007\/s11864-001-0068-7","type":"journal-article","created":{"date-parts":[[2007,7,16]],"date-time":"2007-07-16T18:23:48Z","timestamp":1184610228000},"page":"459-471","source":"Crossref","is-referenced-by-count":64,"title":["Metastatic colorectal cancer"],"prefix":"10.1007","volume":"2","author":[{"given":"Hedy Lee","family":"Kindler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"68_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","volume":"51","author":"RT Greenlee","year":"2001","unstructured":"Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics 2001. CA Cancer J Clin 2001, 51:15\u201336.","journal-title":"CA Cancer J Clin"},{"key":"68_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0889-8588(05)70451-2","volume":"11","author":"JA Kroser","year":"1997","unstructured":"Kroser JA, Bachwich DR, Lichtenstein GR: Risk factors for the development of colorectal carcinoma and their modification. Hematol Oncol Clin North Am 1997, 11:547\u2013577.","journal-title":"Hematol Oncol Clin North Am"},{"key":"68_CR3","unstructured":"Kindler HL, Schilsky RL: Colorectal cancer. In In Oncologic Therapies, edn. 2. Edited by: Vokes EE, Golomb HM. Berlin, Springer-Verlag, in press."},{"key":"68_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/bmj.321.7260.531","volume":"321","author":"PC Simmonds","year":"2000","unstructured":"Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and metaanalysis. Colorectal Cancer Collaborative Group. BMJ 2000, 321:531\u2013535.","journal-title":"BMJ"},{"key":"68_CR5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1200\/JCO.1992.10.6.896","volume":"10","author":"Advanced Colorectal Cancer Meta-Analysis Project","year":"1992","unstructured":"Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10:896\u2013903.","journal-title":"J Clin Oncol"},{"key":"68_CR6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.1998.16.1.301","volume":"16","author":"Meta-analysis Group in Cancer","year":"1998","unstructured":"Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16:301\u2013308.","journal-title":"J Clin Oncol"},{"key":"68_CR7","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1200\/JCO.1995.13.6.1303","volume":"13","author":"C Leichman","year":"1995","unstructured":"Leichman C, Fleming T, Muggia F, et al.: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995, 13:1303\u20131311.","journal-title":"J Clin Oncol"},{"key":"68_CR8","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.1993.11.5.909","volume":"11","author":"Y Shimada","year":"1993","unstructured":"Shimada Y, Yoshino M, Wakui A, et al.: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993, 11:909\u2013913.","journal-title":"J Clin Oncol"},{"key":"68_CR9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","volume":"15","author":"P Rougier","year":"1997","unstructured":"Rougier P, Bugat R, Douillard J, et al.: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997, 15:251\u2013260.","journal-title":"J Clin Oncol"},{"key":"68_CR10","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1200\/JCO.1997.15.8.2910","volume":"15","author":"HC Pitot","year":"1997","unstructured":"Pitot HC, Wender DB, O\u2019Connell MJ, et al.: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997, 15:2910\u20132919.","journal-title":"J Clin Oncol"},{"key":"68_CR11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.1996.14.3.709","volume":"14","author":"JA Conti","year":"1996","unstructured":"Conti JA, Kemeny NE, Saltz LB, et al.: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14:709\u2013715.","journal-title":"J Clin Oncol"},{"key":"68_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","volume":"352","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Pyrhonen S, James R, et al.: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413.","journal-title":"Lancet"},{"key":"68_CR13","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","volume":"352","author":"P Rougier","year":"1998","unstructured":"Rougier P, VanCutsem E, Bajetta E, et al.: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407\u20131412.","journal-title":"Lancet"},{"key":"68_CR14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New Engl J Med 2000, 343:905\u2013914. The randomized phase III trial that established the superiority of the three-drug regimen of 5-FU, leucovorin, and irinotecan in terms of response rate, survival, and progression-free survival.","journal-title":"New Engl J Med"},{"key":"68_CR15","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"J Douillard","year":"2000","unstructured":"Douillard J, Cunningham D, Roth A, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000, 355:1041\u20131047.","journal-title":"Lancet"},{"key":"68_CR16","first-page":"1","volume":"344","author":"DJ Sargent","year":"2001","unstructured":"Sargent DJ, Niedzwiecki D, O\u2019Connell MJ, Schilsky RL: Recommendations for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. New Engl J Med 2001, 344:1. An important letter to the editor that alerts clinicians to the potential toxicities of combination therapy with 5-FU, leucovorin, and irinotecan.","journal-title":"New Engl J Med"},{"key":"68_CR17","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2000.18.6.1337","volume":"18","author":"E van Cutsem","year":"2000","unstructured":"vanCutsem E, Findlay M, Osterwalder B, et al.: Capecitabine, an oral fluoropyrimidine with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000, 18:1337\u20131345.","journal-title":"J Clin Oncol"},{"key":"68_CR18","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"P Hoff","year":"2001","unstructured":"Hoff P, Ansari R, Batist G, et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19:2282\u20132292.","journal-title":"J Clin Oncol"},{"key":"68_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1634\/theoncologist.5-2-99","volume":"5","author":"S Sharma","year":"2000","unstructured":"Sharma S, Saltz LB: Oral chemotherapeutic agents for colorectal cancer. Oncologist 2000, 5:99\u2013107. Reviews the economic considerations for the development of oral regimens for colorectal cancer.","journal-title":"Oncologist"},{"key":"68_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/ejso.1999.0679","volume":"25","author":"M Cromheecke","year":"1999","unstructured":"Cromheecke M, de Jong KP, Hoekstra HJ: Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol 1999, 25:451\u2013463. An excellent review of treatment strategies for colorectal cancer metastatic to the liver.","journal-title":"Eur J Surg Oncol"},{"key":"68_CR21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1200\/JCO.1997.15.3.938","volume":"15","author":"Y Fong","year":"1997","unstructured":"Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938\u2013946.","journal-title":"J Clin Oncol"},{"key":"68_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/archsurg.135.6.657","volume":"135","author":"AJ Bilchik","year":"2000","unstructured":"Bilchik AJ, Wood TF, Allegra D, et al.: Cryosurgical ablation and radiofrequency ablation for unresectable hepatic neoplasms: a proposed algorithm. Arch Surg 2000, 135:657\u2013664.","journal-title":"Arch Surg"},{"key":"68_CR23","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1200\/JCO.1996.14.7.2047","volume":"14","author":"P Girard","year":"1996","unstructured":"Girard P, Ducreeux M, Baldeyrou P, et al.: Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 1996, 14:2047\u20132053.","journal-title":"J Clin Oncol"},{"key":"68_CR24","first-page":"524","volume":"20","author":"NC Tebbutt","year":"2001","unstructured":"Tebbutt NC, Norman A, Livingston S, et al.: Chemotherapy as initial treatment in patients with unresected primary colorectal cancer and synchronous metastases. Proc Am Soc Clin Oncol 2001, 20:524.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"68_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jnci\/88.5.252","volume":"88","author":"Meta-analysis Group in Cancer","year":"1996","unstructured":"Meta-analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996, 88:252\u2013258.","journal-title":"J Natl Cancer Inst"},{"key":"68_CR26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/JCO.2000.18.2.239","volume":"18","author":"DG Haller","year":"2000","unstructured":"Haller DG: Waiting for the definitive trial of hepatic arterial chemotherapy for colorectal cancer. J Clin Oncol 2000, 18:239\u2013242. A thoughtful discussion of the problems and promise of trials using hepatic arterial infusion.","journal-title":"J Clin Oncol"},{"key":"68_CR27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.2000.18.2.243","volume":"18","author":"M Lorenz","year":"2000","unstructured":"Lorenz M, Muller HH, for the German Cooperative Group on Liver Metastases: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000, 18:243\u2013254.","journal-title":"J Clin Oncol"},{"key":"68_CR28","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJM199912303412702","volume":"341","author":"N Kemeny","year":"1999","unstructured":"Kemeny N, Huang Y, Cohen A, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039.","journal-title":"N Engl J Med"},{"key":"68_CR29","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO.1998.16.8.2739","volume":"16","author":"Y Becouarn","year":"1998","unstructured":"Becouarn Y, Yehou M, Ducreux M, et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer. J Clin Oncol 1998, 16:2739\u20132744.","journal-title":"J Clin Oncol"},{"key":"68_CR30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/oxfordjournals.annonc.a010489","volume":"7","author":"D Machover","year":"1996","unstructured":"Machover D, Diaz-Rubio E, deGramont A, et al.: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7:95\u201398.","journal-title":"Ann Oncol"},{"key":"68_CR31","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938\u20132947. An important trial that demonstrates that the addition of oxaliplatin to 5-FU and leucovorin significantly improves response rates, but not survival.","journal-title":"J Clin Oncol"},{"key":"68_CR32","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.1996.14.3.716","volume":"14","author":"JR Zalcberg","year":"1996","unstructured":"Zalcberg JR, Cunningham D, vanCutsem Cutsem E, et al.: ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex colorectal study group. J Clin Oncol 1996, 14:716\u2013721.","journal-title":"J Clin Oncol"},{"key":"68_CR33","first-page":"801","volume":"16","author":"R Pazdur","year":"1997","unstructured":"Pazdur R, Vincent M: Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 1997, 16:801.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"68_CR34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1200\/JCO.1997.15.3.915","volume":"15","author":"CD Blanke","year":"1997","unstructured":"Blanke CD, Kasimis B, Schein P, et al.: Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 1997, 15:915\u2013920.","journal-title":"J Clin Oncol"},{"key":"68_CR35","first-page":"1006","volume":"18","author":"CJ Punt","year":"1999","unstructured":"Punt CJ, Keizer HJ, Douma J, et al.: Multicenter randomized trial of 5-Flourouracil (5-FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first-line treatment in patients (pts) with advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1999, 18:1006.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"68_CR36","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L","volume":"88","author":"W John","year":"2000","unstructured":"John W, Picus J, Blanke CD, et al.: Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000, 88:1807\u20131813.","journal-title":"Cancer"},{"key":"68_CR37","first-page":"2325","volume":"55","author":"DM Bollag","year":"1995","unstructured":"Bollag DM, McQueney PA, Zhu J, et al.: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995, 55:2325\u20132333.","journal-title":"Cancer Res"},{"key":"68_CR38","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.1994.12.11.2296","volume":"12","author":"R Pazdur","year":"1994","unstructured":"Pazdur R, Lassere Y, Rhodes V, et al.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994, 12:2296\u20132300.","journal-title":"J Clin Oncol"},{"key":"68_CR39","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1517\/13543784.9.7.1635","volume":"9","author":"HL Kindler","year":"2000","unstructured":"Kindler HL, Schilsky RL: Eniluracil. Expert Opin Investig Drugs 2000, 9:1635\u20131649.","journal-title":"Expert Opin Investig Drugs"},{"key":"68_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1054\/bjoc.2000.1236","volume":"83","author":"A Ohtsu","year":"2000","unstructured":"Ohtsu A, Baba H, Sakata Y, et al.: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000, 83:141\u2013145.","journal-title":"Br J Cancer"},{"key":"68_CR41","first-page":"3a","volume":"20","author":"L Saltz","year":"2001","unstructured":"Saltz L, Rubin M, Hochster H, et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001, 20:3a. This important trial demonstrates the activity of the combination of a monoclonal antibody to the epidermal growth factor receptor plus irinotecan in patients refractory to irinotecan.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"68_CR42","first-page":"2053","volume":"6","author":"F Ciardiello","year":"2000","unstructured":"Ciardiello F, Caputo R, Bianco R, et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000, 6:2053\u20132063.","journal-title":"Clin Cancer Res"},{"key":"68_CR43","first-page":"242a","volume":"19","author":"E Bergsland","year":"2000","unstructured":"Bergsland E, Hurwitz H, Fehrenbacher L, et al.: A randomized phase II trial comparing rhuMAb VEGF (Recombinant Humanized monoclonal antibody to vascular endothelial growth factor) plus 5-FU\/leucovorin (FU\/LV) to FU\/LV alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000, 19:242a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"68_CR44","first-page":"116b","volume":"20","author":"C Eng","year":"2001","unstructured":"Eng C, Kindler HL, Stadler WM, et al.: SU5416 in advanced colorectal cancer (CRC): a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol 2001, 20:116b.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"68_CR45","first-page":"142a","volume":"20","author":"J Hwang","year":"2001","unstructured":"Hwang J, Sinicrope F, Safran H, et al.: A Phase II Trial of Irinotecan and Trastuzumab (Herceptin) in Patients (Pts) Overexpressing HER-2\/neu in Metastatic Colorectal Cancer (CRC). Proc Am Soc Clin Oncol 2001, 20:142a.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"68_CR46","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.1999.17.9.2889","volume":"17","author":"KA Foon","year":"1999","unstructured":"Foon KA, John WJ, Chakraborty M, et al.: Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999, 17:2889\u20132895.","journal-title":"J Clin Oncol"},{"key":"68_CR47","first-page":"1010a","volume":"18","author":"C Twelves","year":"1999","unstructured":"Twelves C, Harper P, Cutsem EV, et al.: A phase III trial (SO14796) of Xeloda (Capecitabine) in previously untreated advanced\/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999, 18:1010a.","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-001-0068-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0068-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-001-0068-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T19:31:46Z","timestamp":1652643106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-001-0068-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["68"],"URL":"https:\/\/doi.org\/10.1007\/s11864-001-0068-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]}}}